Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Janabi, A, Yiu, Z Z N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747772/
https://www.ncbi.nlm.nih.gov/pubmed/35024352
http://dx.doi.org/10.2147/PTT.S328575
_version_ 1784630908861546496
author Al-Janabi, A
Yiu, Z Z N
author_facet Al-Janabi, A
Yiu, Z Z N
author_sort Al-Janabi, A
collection PubMed
description Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.
format Online
Article
Text
id pubmed-8747772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87477722022-01-11 Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management Al-Janabi, A Yiu, Z Z N Psoriasis (Auckl) Review Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice. Dove 2022-01-06 /pmc/articles/PMC8747772/ /pubmed/35024352 http://dx.doi.org/10.2147/PTT.S328575 Text en © 2022 Al-Janabi and Yiu. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Al-Janabi, A
Yiu, Z Z N
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
title Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
title_full Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
title_fullStr Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
title_full_unstemmed Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
title_short Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
title_sort biologics in psoriasis: updated perspectives on long-term safety and risk management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747772/
https://www.ncbi.nlm.nih.gov/pubmed/35024352
http://dx.doi.org/10.2147/PTT.S328575
work_keys_str_mv AT aljanabia biologicsinpsoriasisupdatedperspectivesonlongtermsafetyandriskmanagement
AT yiuzzn biologicsinpsoriasisupdatedperspectivesonlongtermsafetyandriskmanagement

Ejemplares similares